Camp4 Therapeutics Corporation
CAMP
$3.72
$0.246.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.01M | 1.51M | 652.00K | 0.00 | 350.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.01M | 1.51M | 652.00K | 0.00 | 350.00K |
| Cost of Revenue | 40.19M | 39.23M | 38.83M | 39.49M | 39.61M |
| Gross Profit | -37.18M | -37.72M | -38.18M | -39.49M | -39.26M |
| SG&A Expenses | 16.50M | 15.59M | 14.91M | 13.04M | 12.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.69M | 54.82M | 53.74M | 52.53M | 51.70M |
| Operating Income | -53.68M | -53.31M | -53.09M | -52.53M | -51.35M |
| Income Before Tax | -51.78M | -51.77M | -51.79M | -51.50M | -49.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.78 | -51.77 | -51.79 | -51.50 | -49.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.78M | -51.77M | -51.79M | -51.50M | -49.71M |
| EBIT | -53.68M | -53.31M | -53.09M | -52.53M | -51.35M |
| EBITDA | -51.99M | -51.63M | -51.39M | -50.82M | -49.63M |
| EPS Basic | -26.20 | -51.58 | -77.53 | -107.04 | -112.06 |
| Normalized Basic EPS | -16.38 | -32.24 | -48.46 | -66.90 | -70.04 |
| EPS Diluted | -26.20 | -51.58 | -77.53 | -107.04 | -112.06 |
| Normalized Diluted EPS | -16.38 | -32.24 | -48.46 | -66.90 | -70.04 |
| Average Basic Shares Outstanding | 58.12M | 38.44M | 18.76M | 1.94M | 1.78M |
| Average Diluted Shares Outstanding | 58.12M | 38.44M | 18.76M | 1.94M | 1.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |